Rezolute, INC 8-K filings

Rezolute's oral drug RZ402 demonstrated a statistically significant reduction in central subfield thickness (CST) in patients with diabetic macular edema (DME) in a Phase 2 trial.

Rezolute, Inc. has entered into a private placement agreement to sell 1,500,000 shares of common stock at $4.00 per share, raising approximately $6.0 million to fund clinical research and development.

Rezolute, Inc. has announced the pricing of a $60 million public offering of common stock and pre-funded warrants to fund research and development and for working capital.

Rezolute reports positive topline results from a Phase 2 study of RZ402, showing significant reduction in macular edema in patients with diabetic macular edema.

Rezolute, Inc. successfully held its 2024 annual meeting, electing all director nominees and ratifying Grant Thornton LLP as its independent auditor.

Rezolute announced its third quarter fiscal 2024 financial results and provided updates on its clinical programs, including the ongoing Phase 3 study for RZ358 and the completed Phase 2 study for RZ402.

Rezolute, Inc. will present sub-analysis data from its Phase 2 RIZE study on RZ358 for congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, highlighting overnight hypoglycemia benefits.

Rezolute Inc. exchanged 3 million common shares for pre-funded warrants and appointed a new independent accounting firm, Grant Thornton LLP, replacing Plante & Moran, PLLC.

Rezolute's preclinical study validates RZ358's potential to treat hypoglycemia caused by both islet and non-islet cell tumors, potentially doubling the addressable patient population.

Rezolute, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Rezolute reports its second quarter fiscal 2024 results, highlighting progress in clinical trials for RZ358 and RZ402, and the appointment of a new CFO.

Rezolute, Inc. has appointed Daron Evans as Chief Financial Officer and received an Innovation Passport designation in the UK for its drug RZ358.